FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:83-85 July 2, 2009 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Mauer, M. PubMed Citation

The hypothesis that inhibition of the renin–angiotensin system may be effective in preventing diabetic nephropathy was based on a large body of evidence.¹ Positive findings from studies in animal models and subsequent clinical trials fostered enthusiastic hope that systematic use of agents blocking the renin–angiotensin system in the management of diabetic nephropathy would reduce the risk of end-stage renal disease.^2,3,4 Out of such studies was born a concept that gained wide acceptance: inhibition of the renin–angiotensin system in patients with diabetes is beneficial with regard to both early and advanced stages of nephropathy. As an extension, studies were initiated to . . . [Full Text of this Article]

Source Information

From the Department of Medicine, Division of Endocrinology, University of Toronto, Toronto (B.A.P.); and the Beetham Eye Institute (L.P.A.) and the Research Division (A.S.K.), Joslin Diabetes Center and Harvard Medical School, Boston.

This article has been cited by other articles:

• (2009). ACE Inhibitors and ARBs for Preventing Nephropathy and Retinopathy in Type 1 Diabetes. JWatch General 2009: 1-1 [Full Text]